Scinai Immunotherapeutics Secures $10 Million Equity Purchase Agreement

Scinai Immunotherapeutics ( (SCNI) ) has issued an announcement.

On March 3, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the company to sell up to $10 million of its American Depositary Shares over the next 36 months. This agreement provides Scinai with financial flexibility and potential capital to support its operations, though Yorkville is not obligated to purchase shares exceeding 9.99% of the company’s voting power. The transaction is subject to various conditions, including SEC registration, and aims to strengthen Scinai’s market position by securing a committed investor.

More about Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on the development and commercialization of immunotherapeutic products. The company is based in Jerusalem, Israel, and its primary offerings include American Depositary Shares (ADSs) listed on the Nasdaq Stock Market under the symbol ‘SCNI’.

YTD Price Performance: 2.91%

Average Trading Volume: 12,444

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $3.02M

For an in-depth examination of SCNI stock, go to TipRanks’ Stock Analysis page.